ClinicalTrials.gg
Status unknownNCT04455581Updated Jul 2, 2020

A Study to Determine the Safety, Tolerability, and Efficacy of SHR-1209 in Patients With Familial Hypercholesterolemia

A Phase 2 interventional study of SHR-1209 in Familial Hypercholesterolemia, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Status unknown. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2020-07-02.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jun 2020), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
8
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Study summary

The study is being conducted to evaluate the efficacy, safety and tolerability of SHR-1209 in subjects with familial hypercholesterolemia. 8 eligible patients (aged ≥18 years) with familial hypercholesterolemia, on stable maximum tolerable dose lipid-regulating therapy for at least 28 days, to receive subcutaneous SHR-1209, follow up 8 weeks. The primary endpoint was percentage change in LDL cholesterol from baseline at week 12 .

02

Conditions studied

  • Familial Hypercholesterolemia
03

In context

Hyperlipoproteinemia Type II

249 studies on the registry are indexed under Hyperlipoproteinemia Type II; 56 are open to participants now.

This study's planned enrollment of 8 is below the median of 134 across 178 interventional studies indexed under Hyperlipoproteinemia Type II.

Browse Hyperlipoproteinemia Type II studies →

Lead sponsor

Jiangsu HengRui Medicine Co., Ltd. is the lead sponsor of 573 studies on the registry; 88 are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 1 (10%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males and females ≥ 18 years of age
  • Diagnosis of homozygous familial hypercholesterolemia
  • Stable lipid-lowering therapies for at least 28 days
  • LDL cholesterol ≥ 130 mg/dl (3.4 mmol/L)
  • Triglyceride ≤ 400 mg/dL (4.5 mmol/L)
  • Bodyweight of ≥ 40 kg at screening.

Exclusion criteria

Exclusion Criteria:

  • LDL or plasma apheresis within 8 weeks prior to randomization
  • (NYHA) class III or IV or last known \< 30%
  • Myocardial infarction, unstable angina, percutaneous coronary intervention, coronary artery bypass graft or stroke within 3 months of randomization, Planned cardiac surgery or revascularization, Uncontrolled cardiac arrhythmia
  • Liver transplant history.
  • Uncontrolled hypertension.
  • Moderate to severe renal dysfunction.
  • Active liver disease or hepatic dysfunction.
  • Known sensitivity to any of the products to be administered during dosing
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
8 participants (estimated)

Study arms

  • Experimental
    Treatment group

    SHR-1209 administered by subcutaneous injection Atorvastatin or Rosuvastatin combined with Ezetimibe oral

    Drug: SHR-1209

Interventions

  • SHR-1209 administered by subcutaneous injection Atorvastatin or Rosuvastatin combined with Ezetimibe oral

06

What researchers measure

Primary outcomes

  1. Percent Change from Baseline in LDL-C at Week 12

    Time frame: Week 12

Secondary outcomes

  1. Change From Baseline in LDL-C at Week 12

    Time frame: Week 12

  2. Percent Change From Baseline in LDL-C at the Mean of Weeks 10 and 12

    Time frame: Weeks 10 and 12

  3. Change From Baseline in LDL-C at the Mean of Weeks 10 and 12

    Time frame: Weeks 10 and 12

  4. Percent Change From Baseline in the Total Cholesterol at the Mean of Weeks 10 and 12

    Time frame: Weeks 10 and 12

  5. Percent Change From Baseline in the Total Cholesterol at Week 12

    Time frame: Week 12

  6. Percent Change From Baseline in HDL-C at the Mean of Weeks 10 and 12

    Time frame: Weeks 10 and 12

  7. Percent Change From Baseline in HDL-C at Week 12

    Time frame: Week 12

  8. Percent Change From Baseline in Non-HDL-C at the Mean of Weeks 10 and 12

    Time frame: Weeks 10 and 12

  9. Percent Change From Baseline in Non-HDL-C at Week 12

    Time frame: Week 12

  10. Percent Change From Baseline in Triglycerides at the Mean of Weeks 10 and 12

    Time frame: Weeks 10 and 12

  11. Percent Change From Baseline in Triglycerides at Week 12

    Time frame: Week 12

  12. Percent Change From Baseline in Apo B at the Mean of Weeks 10 and 12

    Time frame: Weeks 10 and 12

  13. Percent Change From Baseline in ApoB at Week 12

    Time frame: Week 12

  14. Percent Change From Baseline in Apo A1 at the Mean of Weeks 10 and 12

    Time frame: Weeks 10 and 12

  15. Percent Change From Baseline in Apo A1 at Week 12

    Time frame: Week 12

  16. Percent Change From Baseline in Lipo(a) at the Mean of Weeks 10 and 12

    Time frame: Weeks 10 and 12

  17. Percent Change From Baseline in Lipo(a) at Week 12

    Time frame: Week 12

  18. Number of investigational product-related adverse events

    Time frame: Weeks 12 and 20

  19. Number of ADA and Nab

    Time frame: Week 20

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2020; primary completion for Jun 2021, 9 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 29, 2020
First posted
Jul 2, 2020
StartEst.
Sep 1, 2020
Primary completionEst.
Jun 30, 2021
CompletionEst.
Aug 31, 2021
Last update
Jul 2, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 2, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04455581
Responsible party
Sponsor
First posted
Jul 2, 2020
Start date
Sep 1, 2020 (estimated)
Primary completion
Jun 30, 2021 (estimated)
Completion
Aug 31, 2021 (estimated)
Last update
Jul 2, 2020

Study contacts

Bin Zhang, Medial Manager
Contact
zhangbin@hrglobe.cn
+86 13671548369
Bo Zhu, Medical Director
Contact
zhubo@hrglobe.cn
+86 13380043088

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Recaticimab

Start the discussion